Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1

Gerlach, Gerald-F.; Anderson, Carol; Klashinsky, S; Rossi-Campos, A.; Potter, Andrew; Willson, Philip

doi:10.1128/iai.61.2.565-572.1993

Cited by 68 publications

(52 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The GFP expression cassette serves as an insertional inactivation element as well as an expression tracing tool, which may be used to analyze tissue tropism of A. pleuropneumoniae. The promoter omlA is a short element and has been widely used in A. pleuropneumoniae to drive constitutive and strong expression of foreign genes [15]. Here, it was used to drive efficient expression of the sacB gene.…”

Section: Discussionmentioning

confidence: 99%

Construction and characterization of a live, attenuated apxIICA inactivation mutant ofActinobacillus pleuropneumoniaelacking a drug resistance marker

Bei

Lin

et al. 2005

FEMS Microbiology Letters

View full text Add to dashboard Cite

The apxIIC gene of Actinobacillus pleuropneumoniae serotype 7 was inactivated by homologous recombination using a sucrose counter-selectable marker system, resulting in a mutant strain that had no antibiotic resistance marker and expressed an inactivated ApxII toxin. The safety and immunogenicity of the mutant were evaluated in mice. The mutant strain caused no adverse effects in mice at doses up to 2 x 10(9) CFU via the intraperitoneal route while the parental strain induced total mortality at a dose of 2 x 10(7) CFU. Mice vaccinated intraperitoneally with the mutant strain had 100% and 70% protection against homologous (serotype 7) or heterologous (serotype 1, 3) challenge with A. pleuropneumoniae, respectively. The A. pleuropneumoniae mutant strain HB04C- and the counterselection method used in the study show promise in developing effective live vaccines for porcine pleuropneumonia and for other infections diseases of the respiratory system.

show abstract

Section: Discussionmentioning

confidence: 99%

Construction and characterization of a live, attenuated apxIICA inactivation mutant ofActinobacillus pleuropneumoniaelacking a drug resistance marker

Bei

Lin

et al. 2005

FEMS Microbiology Letters

View full text Add to dashboard Cite

show abstract

“…OmlA from Actinobacillus pleuropneumoniae was prepared as previously described (Gerlach et al 1993). Biphasix VTAs (PharmaDerm Laboratories Ltd, Saskatoon, SK, Canada) were prepared as described previously (Foldvari 1998;.…”

Section: Antigen and Delivery Systemsmentioning

confidence: 99%

Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model

Alcon

Baca-Estrada

Vega-Lopez

et al. 2005

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

The nasal mucosa is an important arm of the mucosal system since it is often the first point of contact for inhaled antigens. The ineffectiveness of the simple delivery of soluble antigens to mucosal membranes for immunization has stimulated extensive studies in appropriate delivery systems and adjuvants. We have evaluated biphasic lipid vesicles as a novel intranasal (i.n.) delivery system (designated as vaccine targeting adjuvant, VTA) containing bacterial antigens and CpG oligodeoxynucleotides (ODNs). Results show that administration of antigen and CpG ODNs in biphasic lipid vesicles resulted in greater induction of IgA levels in serum (P< 0.05) and mucosal antibody responses such as IgA in nasal secretions and lung (P< 0.01) after immunization with a combined subcutaneous (s.c.)/i.n. as compared to s.c./s.c. approach. Based on antibody responses, VTA formulations were found to be suitable as delivery systems for antigens and CpG ODNs by the intranasal route, resulting in a Th2-type of immune response, characterized by IgG1 and IL-4 production at the systemic level.

show abstract

“…Primers were designed from the published DNA sequences [8^10], and synthesized to amplify the omlA gene from strain WF83. The sequence of the primers and their positions relative to the ¢rst base of the omlA I ORF [8] are as follows : primer F1, 5P-TGTAAACTTTAGACTTTATATTTTG-3P (nucleotide (nt) 3122 to 397); and primer R1, 5P-GAT-ATCTTTTACCGATGCACTATT-3P (complementary to nt 1186^1163). The PCR conditions were the same as described previously [9].…”

Section: Pcr Ampli¢cation and Nucleotide Sequence Analysis Of The Omlmentioning

confidence: 99%

Demonstration of the third antigenically distinct outer membrane lipoprotein (OmlA) in Actinobacillus pleuropneumoniae serotype 7

Ito

1998

FEMS Microbiology Letters

View full text Add to dashboard Cite

The gene encoding an outer membrane lipoprotein (OmlA) of Actinobacillus pleuropneumoniae strain WF83 (serotype 7 reference strain), designated omlA U , was sequenced. The amino acid sequence of OmlA U showed 64.5 and 71.6% identity to that of OmlA from serotypes 1 (OmlA I ) and 5 (OmlA S ), respectively. The first 134 amino acids of OmlA U were identical to those of OmlA S . A Southern blot analysis revealed the presence of a gene highly homologous to the omlA U in the reference strains of serotypes 3, 4, 6, and 7. A Western blot analysis using a specific antiserum against a recombinant OmlA U detected expression of the homologous proteins in the serotypes 4, 6, and 7 reference strains and a serotype 3 field strain, but not in a serotype 3 reference strain. The data demonstrate the third antigenically distinct OmlA is expressed in A. pleuropneumoniae. z 1998 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.

show abstract

Molecular characterization of a protective outer membrane lipoprotein (OmlA) from Actinobacillus pleuropneumoniae serotype 1

Cited by 68 publications

References 32 publications

Construction and characterization of a live, attenuated apxIICA inactivation mutant ofActinobacillus pleuropneumoniaelacking a drug resistance marker

Construction and characterization of a live, attenuated apxIICA inactivation mutant ofActinobacillus pleuropneumoniaelacking a drug resistance marker

Intranasal immunization using biphasic lipid vesicles as delivery systems for OmlA bacterial protein antigen and CpG oligonucleotides adjuvant in a mouse model

Demonstration of the third antigenically distinct outer membrane lipoprotein (OmlA) in Actinobacillus pleuropneumoniae serotype 7

Contact Info

Product

Resources

About